Grant: Catalyst Grant: Post Market Drug Safety and Effectiveness
University of British Columbia
$98,000.00
Sapropterin for treatment of patients with Phenylketonuria: Identification of subpopulations with substantial clinical benefit
FY 2011-12
Summary
Phenylketonuria (PKU) is a rare genetic condition affecting the breakdown of the aminoacid phenylalanine (phe). PKU results in intellectual disability if untreated. Treatment consists of a very low protein diet and patients are not always able to adhere to arduous dietary restrictions. Sapropterin is the first drug which may result in an improved tolerance of protein and diet liberalizaton. However, not all patients are responders and response may not be significant enough to justify the high costs of the drug. We will establish a national network to test patients for their response to Sapropterin and develop national criteria to identify those who benefit most.
Department
Program
Catalyst Grant: Post Market Drug Safety and Effectiveness
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
244059
Name
Stockler Sylvia
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Clinical
Prcname2
Catalyst Grant: Post Market Drug Safety and Effectiveness
Projecttitle
Sapropterin for treatment of patients with Phenylketonuria: Identification of subpopulations with substantial clinical benefit
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$98,000
Cihrequipment2
$0
Programname2
Catalyst Grant: Post Market Drug Safety and Effectiveness
Keyworddelim
Children; Clinical Benefit; Expensive Drug For Rare Disease; Funding To Create Evidence; Kuvan; Outcome; Phenylketonuria; Sapropterin Dihydrochloride
Abstract
Phenylketonuria (PKU) is a rare genetic condition affecting the breakdown of the aminoacid phenylalanine (phe). PKU results in intellectual disability if untreated. Treatment consists of a very low protein diet and patients are not always able to adhere to arduous dietary restrictions. Sapropterin is the first drug which may result in an improved tolerance of protein and diet liberalizaton. However, not all patients are responders and response may not be significant enough to justify the high costs of the drug. We will establish a national network to test patients for their response to Sapropterin and develop national criteria to identify those who benefit most.
Competitiondate
201110
Approvedterm2
1 yr 0 mth
Pinamesdelim
Stockler, Sylvia
Approvedterm
1 an 0 mois
Cihrcontribution2
DSEN~ $68,000~ $0~Knowledge Translation Branch~ $30,000~ $0~